169, Harrison avenue Boston, MA 02111.
+1 857-302-4704

Novel Products that enhance value growth in the Antithrombotic Drugs Market

One of the leading causes of mobility and mortality in the world is associated with venous thrombosis and arterial thrombosis. Ever since the 1930s, antithrombotic therapy has been used as the key medical therapy for the treatment of thrombotic diseases. However, the implementation of these antithrombotic drugs has led to one of the terrified iatrogenic illnesses of bleeding. Nevertheless, the development of new evidence has risen the potential improvement in antithrombotic drugs that possess the ability to eradicate or cause no bleeding.
In comparison with traditional therapies, these varied novel products are developed with advances, including enhanced drugs action and clinical profiles. Moreover, the conclusion of a wide range of research with evidence has defined the functioning of Factor X that can prevent coagulation by abbreviating the formation of thrombus without the danger of bleeding. Thus, Factor X is under detailed examination to develop novel anticoagulant therapies.
The antithrombotic drugs market has a classification in three main classes – Anticoagulants, Antiplatelet and Thrombin Inhibitors. In short, anticoagulants and antiplatelet drugs are commonly known as blood thinners, and the Thrombin Inhibitors delay the activity of thrombin that prevents the formation of a clot in the blood.
Below is the list of some Top Products from the Above Three Classes that are leading the Antithrombotic Drugs Market:
Xarelto (Rivaroxaban)
In terms of revenue, Xarelto is known to hold the best performance in the market. This thrombin inhibitor is part of a drug class – direct factor XA inhibitors. The product is marketed by Bayer across the globe, and another company Jansen Pharmaceutical markets in the United States. Currently, Xarelto is a patent-protected product, which is expected to expire not before 2020. Moreover, the product has managed to extend its patent protection until 2024, specifically in the U.S. The product is also said to be safeguarded from the threat of generic competition, therefore, to witness blooming prospects in future.
Eliquis (Apixaban)
Eliquis is another leading factor XA inhibitor, holding a majority market share in terms of revenue. The product is marketed by the two companies primarily, Bristol-Myers Squib and Pfizer. Eliquis holds its patent protection until the year 2023 in the United States and by 2022 in the EU. In addition, Eliquis is also anticipated to continue its revenue lead over the coming years.
Pradaxa (Dabigatran Etexilate Mesylate)
Over a period of time, Pradaxa is one to be the most known direct thrombin inhibitor drug in the market. On the contrary, the product sale has seen a slack due to the emergence of other thrombin inhibitors. The company marketing Pradaxa is Boehringer Ingelheim. The product generated a revenue of $1.8 billion in 2015 and is projected to grow at a steady pace in the coming years. Pradaxa patent has been expired recently in the year 2018.
LOVENOX (ENOXAPARIN)
Lovenox is an anticoagulant drug marketed and commercialized by Sanofi. It is low molecular weight heparin, indicated for the prophylaxis of deep vein thrombosis that may lead to pulmonary embolism. It also helps in preventing pulmonary embolism in patients with knee/hip-replacement surgery, abdominal surgery or medical patients with severely restricted mobility during acute illness. However, the patent expiration of Lovenox in 2012 has led to a strong decline in its revenue sales.
Plavix (Clopidogrel)
Plavix was jointly developed and marketed by Sanofi and Bristol-Myers Squibb. The patent of the drug expired in 2012, which is responsible for the major decline in its revenues. Plavix and its generic versions earned revenues of $2.2 billion in 2015, but its revenue graph is expected to witness a further decrease in the coming years.
One of the top concern acknowledged by the operating players in the market is the safety of the antithrombotic drugs, obligated to its precarious aftermath, including redness, liver damage, a mild burning sensation, itching etc. Hence, the market companies are striving to ongoing technological innovations to completely eradicate these allergic reactions from the drugs, making them safer.

Inkwood Research

Author: Inkwood Research

We at Inkwood research provide you with not just consulting services but also with syndicated and customized research reports which help advance your business further.
Like
Like Love Haha Wow Sad Angry

Related Posts

Leave a comment